Group 1 - The company reported revenue of RMB 234 million for the six months ending June 30, 2025, with a significant increase in sales of its product, Olverembatin (耐立克), which rose by RMB 105 million or 93% to RMB 217 million compared to the same period in 2024 [1] - Research and development expenses increased by RMB 84.5 million or 19.0% to RMB 529 million, primarily due to increased external R&D costs associated with ongoing global clinical trials [1] Group 2 - The company's core products, Olverembatin and Lisatoclax, are developed to treat various major hematologic malignancies and solid tumors, with a projected market size exceeding USD 160 billion for these specific blood system diseases by 2035 [2] - The company has established collaborations with leading biotechnology and pharmaceutical companies, including partnerships with Innovent Biologics and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer [3] - The company has also formed research collaborations with prominent research institutions such as Dana-Farber Cancer Institute, Mayo Clinic, MD Anderson Cancer Center, National Cancer Institute, and the University of Michigan [3]
亚盛医药-B发布中期业绩 收益2.34亿元 耐立克 (奥雷巴替尼)在中国的产品销售同比大幅增长93%